USX:AFFX - Affymetrix Inc (USD 14.01) Affymetrix Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance
Note: This stock seems to be inactive

USD 14.01    +0.020 (+0.14%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

31 Mar 2016


31 Mar 2016

Day Change: 0.020 (0.14%)

52 Wk Range: 8.28 - 16.15

Day's Range: 14.0 - 14.05

Last Volume: 5,030,402

Current Yield: 0%

Projected Yield: 0%

Open: USD 14.02

Metric AFFX S.Median
Beta NA NA
E.Shortfall NA NA
Liquidity NA NA


31 Mar 2016

PE: 111.807

Market Cap: 1.1B

Price Over Book: 3.333

Price Over Sales: 3.14

Return On Assets: 1.8%

Return On Equity: 3%

Price Over NAV: [Friends Only]


CEO: Franklin R. Witney

Headquarters: Wilmington

Employees: 1,150

Sector: Health Technology

Industry: Medical Specialties

Useful Links


Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line; products with clinical diagnostic and research applications, such as the CytoScan and OncoScan products; GeneTitan instrument system that runs genotyping and gene expression array plates; and QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers and other biological and health care manufacturers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta Plex assays for low to mid-plex experiments. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. It has collaboration agreement with Cytox Ltd. The company was founded in 1991 and is headquartered in Santa Clara, California.